Trial Profile
A Phase Ia/Ib Study Assessing Single and Multiple Doses of CDI-31244: A Non-Nucleoside Inhibitor in Healthy and Hepatitis C Virus-Infected Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs CC 31244 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; First in man
- Sponsors Cocrystal Pharma Inc
- 15 Aug 2017 Results published in a Cocrystal Pharma media release.
- 18 Jul 2017 Status changed from recruiting to completed.
- 03 Apr 2017 According to a Cocrystal Pharma Inc media release, interim results from the study were presented at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL).